Crossmark

Antipsychotic-induced prolactin elevation in premenopausal women with schizophrenia: associations with estrogen, disease severity and cognition

Published Online: 2024-07-12

Published Print: 2024-12

Authors

Brand, Bodyl A. https://orcid.org/0000-0003-2383-0851
de Boer, Janna N.

Willemse, Elske J. M.

Weickert, Cynthia S.

Sommer, Iris E.

Weickert, Thomas W.
License Information

Text and Data Mining valid from 2024-07-12

Version of Record valid from 2024-07-12
More Information

Article History

Received: 18 July 2023

Accepted: 26 June 2024

First Online: 12 July 2024

Declarations

:

: For the European clinical trial, ethical permission was obtained from the Medical Ethical committee of the University Medical Centre of Utrecht (16–103) in the Netherlands. For the Australian study, ethical permission was obtained from the University of New South Wales (07/121 and 09/187) and the South Eastern Sydney and Illawarra Area Health Service (07-259) and the Queen Elizabeth Hospital Ethics and Human Research Committee, Adelaide (2010188) for Australian subjects. Studies were carried out in accordance with the Declaration of Helsinki of 1975, as revised in 2008. All participants gave written informed consent prior to inclusion in the study.

: CSW is a recipient of a National Health and Medical Research Council (Australia) Investigators Grant Leadership 3 (RG210864). BAB, JNB, EJMW, IEC, and TWW declare they have no financial interest.

: Not applicable.

Document is current